Overview

Nimotuzumab High-risk, Locally Advanced Squamous Cell Carcinoma of the Cervix

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
The efficacy and safety of nimotuzumab in the treatment of high-risk, locally advanced squamous cell carcinoma of the cervix.
Phase:
PHASE2
Details
Lead Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Treatments:
nimotuzumab